Iziphumo (i-Abstract # 519) ziya kuboniswa namhlanje ngo-10: 00 am ET ngexesha leseshoni ekhawulezayo ye-abstract kwi-2022 American Society for Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.
UGqr. Tanios S. Bekaii-Saab, umphandi wophononongo lwe-KRYSTAL-1, uthe, “Ii-cancer zesisu zezinye zezona zixhaphakileyo ze-cancer kwaye ziyaqhubeka nokunxulunyaniswa neziphumo ezibi zokusinda nangona kukho inkqubela phambili yamva nje, ngakumbi kwizigulana ezine-GI tumors Utshintsho lwe-KRASG12C Idatha entsha yeklinikhi eboniswe kwi-ASCO GI ibonisa ukuba i-adagrasib, inhibitor ye-KRASG12C, ibonise umsebenzi othembisayo wekliniki kwizigulana ezinomhlaza we-pancreatic kunye namanye amathumba e-GI. Ezi ziphumo zakhela kwidatha yeklinikhi ye-adagrasib ebixelwe ngaphambili kwi-colorectal kunye ne-pancreatic cancers, kwaye iyakhuthaza kakhulu, iqinisekisa uphando olongezelelweyo lwe-adagrasib kwesi silungiselelo. "
Isishwankathelo seziphumo zoNyango
Ukusukela nge-10 kaSeptemba 2021, iseti esezantsi yezigulana ezine-GI zomhlaza ezigcina utshintsho lwe-KRASG12C ababhaliswe kwi-adagrasib monotherapy arm (n=30) bafumene ubuncinci imigca emibini yangaphambili yonyango lwenkqubo ye-anticancer, kwaye babenolandelelwano oluphakathi lweenyanga ezi-6.3 .
• Kwizigulane ezivandlakanywayo (n=27), izinga lempendulo yenjongo (ORR) yayingama-41% kwaye izinga lokulawula isifo (DCR) laliyi-100%. Kwizigulane ezivavanyayo ezinomhlaza we-pancreatic (n = 10), izinga lokuphendula (RR) laliyi-50%, kubandakanywa ne-1 engaqinisekanga impendulo engaphelelanga (PR); ubude bexesha lokuphendula (mDOR) ziinyanga ze-7.0, kunye nokulandelelaniswa kweenyanga ze-8.1. Kwizigulane ezinezinye izicubu ze-GI (n = 17), i-RR yayiyi-35%, kunye nee-PRs ezimbini ezingaqinisekanga; i-mDOR ibiziinyanga ezisi-7.9 kwezi zigulana, nolandelelwano oluphakathi lweenyanga ezi-6.3.
• I-median progression free survival (mPFS) kwizigulane ezinomdlavuza we-pancreatic ziinyanga ze-6.6 (i-95% ye-Confidence Interval, CI: 1.0, 9.7), kunye nezigulane ezinezinye ii-tumors ze-GI, i-mPFS yayiyi-7.9 iinyanga (95% CI 6.90-). 11.30).
• Kuluhlu olupheleleyo lwezigulane ezine-KRASG12C-mutated GI zomhlaza ezivavanyiweyo kweli qela, i-adagrasib inyamezeleke kakuhle, kunye neprofayili elawulekayo yokhuseleko. Iziganeko ezimbi ezinxulumene nonyango lweBakala 3/4 (TRAEs) zabonwa kwi-27% yezigulane eziphathwe nge-adagrasib, ngaphandle kwe-TRAEs ekhokelela ekuyekisweni konyango, kwaye akukho Grade 5 TRAEs ebonwayo.
"Sikholelwa ukuba i-adagrasib ineprofayili eyahlukileyo ye-molecular, kwaye idatha evezwe kwi-ASCO GI ixhasa ngakumbi iprofayili yayo engcono kakhulu eklasini," watsho uCharles M. Baum, MD, Ph.D., umsunguli, umongameli kunye nentloko yophando kunye uphuhliso, iMirati Therapeutics, Inc. “Iziphumo zibonise umsebenzi omhle wezonyango kwizigulana ezine-KRASG12C-mutated GI zomhlaza ezinyangwa nge-agent enye i-adagrasib, ngakumbi kwezo ezinomhlaza wepancreatic apho ukhetho lunqongopheleyo. Siyaqhubeka nokuvavanya ngokungqongqo i-adagrasib njengearhente enye kwaye ngokudibeneyo namanye amayeza omhlaza kwisicwangciso sophuhliso esibanzi sokunceda abantu abaninzi abaphila nomhlaza. "
INTO ONOKUYITHATHA KWELI NQAKU:
- As of September 10, 2021, the subset of patients with GI cancers harboring a KRASG12C mutation enrolled in the adagrasib monotherapy arm (n=30) received at least two prior lines of systemic anticancer therapies, and had a median follow up of 6.
- Bekaii-Saab, an investigator of the KRYSTAL-1 study, commented, “Gastrointestinal cancers are some of the most common cancers and continue to be associated with poor survival outcomes despite recent advances, especially in patients with GI tumors harboring a KRASG12C mutation.
- We continue to aggressively evaluate adagrasib as a single agent and in combination with other cancer medicines in a broad development plan to help more people living with cancer.
